Skip to content

Study · Randomized controlled trial · 2005

2 results

[Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].

Roshchina IF, Gavrilova SI, Zharikov GA, Kalyn IaB, Kolykhalov IV, Selezneva ND

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2005

PMID15704485 (opens in a new tab)PepBankPUB-15704485
Publisher pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with Alzheimer's disease, the higher Cerebrolysin dose improved cognitive functioning more than the lower dose.

    In plain wordsIn patients with Alzheimer's disease, higher-dose Cerebrolysin improved cognition more than the lower dose.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseCognitive functioning
    Study

    n: not reported in source

    Comparator
    Cerebrolysin 10 ml
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · 4 courses; study conducted during 19 monthsAs given in this study (human).

    Source sentences

    Summary
    The higher cerebrolysin dose was more effictive for cognitive functioning of patients.
    2 context sentences
    Summary · context
    The differences in long-term effects of different medication dosages (10 and 30 ml) were revealed.
    Summary · context
    An open comparative randomized clinico-neuropsychological study of 4 cerebrolysin treatment courses was conducted during 19 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with Alzheimer's disease, progression was significantly greater with Cerebrolysin 10 ml than with the higher dose.

    In plain wordsIn patients with Alzheimer's disease, progression was greater with lower-dose Cerebrolysin than with the higher dose.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseDisease progression
    Study

    n: not reported in source

    Comparator
    Cerebrolysin 30 ml
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    10 ml · 4 courses; study conducted during 19 monthsAs given in this study (human).

    Source sentences

    Summary
    In patients receiving a dosage of 10 ml, the disease progress was significantly more pronounced.
    2 context sentences
    Summary · context
    The differences in long-term effects of different medication dosages (10 and 30 ml) were revealed.
    Summary · context
    An open comparative randomized clinico-neuropsychological study of 4 cerebrolysin treatment courses was conducted during 19 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.